Smith & Nephew plc (LON:SN) Receives Average Rating of “Hold” from Analysts

Smith & Nephew plc (LON:SN) has received a consensus recommendation of “Hold” from the nine brokerages that are currently covering the firm, MarketBeat.com reports. Six research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is GBX 1,293.33.

SN has been the topic of a number of analyst reports. Berenberg Bank dropped their price objective on shares of Smith & Nephew from GBX 1,300 to GBX 1,250 and set a “hold” rating on the stock in a research note on Friday, August 14th. Jefferies Financial Group reissued a “buy” rating and issued a GBX 1,500 price objective on shares of Smith & Nephew in a research report on Friday, September 4th. Citigroup lowered Smith & Nephew to a “buy” rating in a research report on Friday, July 10th. Shore Capital Group reissued a “buy” rating and issued a GBX 1,000 price target on shares of Smith & Nephew in a report on Tuesday, July 21st. Finally, Royal Bank Of Canada lowered their price objective on Smith & Nephew from GBX 1,350 to GBX 1,250 and set a “sector perform” rating for the company in a research note on Thursday, August 6th.

Smith & Nephew Stock Performance

Shares of LON:SN opened at GBX 1,037.50 on Wednesday. The company’s 50 day moving average is GBX 1,104.37 and its 200-day moving average is GBX 1,153.61. The stock has a market cap of £11.37 billion, a P/E ratio of 37.35, a P/E/G ratio of 0.46 and a beta of 0.69. The company has a current ratio of 2.14, a quick ratio of 0.84 and a debt-to-equity ratio of 73.07.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.